| 李 博,许世广,王述民,刘 博,王 通.孔腔镜肺叶切除及淋巴结清扫术围手术期应用不同剂量氨溴索对肺癌患者的作用研究[J].,2020,(5):901-905 |
| 孔腔镜肺叶切除及淋巴结清扫术围手术期应用不同剂量氨溴索对肺癌患者的作用研究 |
| Study on the Effect of Different Doses of Ambroxol on Lung Cancer Patients during Perioperative Period of Single-port Endoscopic Lobectomy and Lymphadenectomy |
| 投稿时间：2019-06-24 修订日期：2019-07-19 |
| DOI：10.13241/j.cnki.pmb.2020.05.022 |
| 中文关键词: 肺癌 单孔腔镜肺叶切除 淋巴结清扫术 氨溴索 剂量 |
| 英文关键词: Single-port endoscopic lobectomy Lymphadenectomy Lung function Inflammatory factors Ambroxol Dose Lung cancer T lymphocyte subsets |
| 基金项目:辽宁省科技厅面上基金项目（20170340741） |
|
| 摘要点击次数: 560 |
| 全文下载次数: 330 |
| 中文摘要: |
| 摘要 目的：探讨围手术期应用不同剂量氨溴索对行单孔腔镜肺叶切除及淋巴结清扫术的肺癌患者的作用。方法：选取本院2017年1月至2018年12月期间收治的124例肺癌患者作为受试者，结合患者意愿按随机数字表法将受试者分为小剂量组（n=41）、中剂量组（n=41）和大剂量组（n=42），术前1d开始给予氨溴索静脉滴注，术后持续7d，比较各组患者临床症状、治疗前后的肺功能、炎症因子、T细胞亚群水平变化及不良反应发生率。结果：大剂量组咳痰容易人数所占比例高于小剂量组，痰液稀薄人数所占比例高于中剂量组及小剂量组（P<0.05）。治疗后大剂量组第一秒用力呼吸容积（FEV1）、FEV1/用力肺活量（FVC）高于中剂量组、小剂量组（P<0.05）。治疗后各组炎症因子水平均高于治疗前，且随着剂量的升高，C反应蛋白（CRP）、白介素-6（IL-6）、白介素-8（IL-8）水平呈降低的趋势（P<0.05）。随着剂量的升高，治疗后的 CD3+、CD4+、CD4+/CD8+均呈升高趋势，CD8+呈降低趋势（P<0.05）。各组不良反应发生率比较无统计学差异（P>0.05）。结论：肺癌患者行单孔腔镜肺叶切除及淋巴结清扫术围手术期应用120mg氨溴索，可加快患者术后恢复，保护患者肺功能，抑制炎症反应，改善患者的免疫功能和临床症状。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of ambroxol at different doses on lung cancer patients undergoing single-port endoscopic lobectomy and lymphadenectomy during perioperative period. Methods: 124 patients with lung cancer who were admitted to our hospital from January 2017 to December 2018 were selected as subjects. The subjects were divided into low dose group (n=41), medium dose group (n=41) and high dose group (n=42) according to the random number table method according to the patients'wishes. Ambroxol was given intravenously 1d before operation, and continued 7d after operation. The changes of clinical symptoms, pulmonary function, inflammatory factors, T lymphocyte subsets before and after treatment and the incidence of adverse reactions in each group were compared. Results: The proportion of expectorants in high dose group was higher than that in low dose group, the proportion of sputum thinning was higher than that of medium dose group and low dose group (P<0.05). The first second forced respiratory volume (FEV1) and FEV1/forced vital capacity (FVC) in high dose group were higher than those in medium dose group and low dose group after treatment (P<0.05). The levels of inflammatory factors after treatment in each group were higher than those before treatment, and with the increase of dose, the levels of C-reactive protein (CRP), interleukin-6 (IL-6), interleukin-8 (IL-8) decreased (P<0.05). With the increase of dose, the CD3+, CD4+, CD4+/CD8+ values after treatment were increased, and the CD8+ value decreased (P<0.05). There was no significant difference in the incidence of adverse reactions among groups (P>0.05). Conclusion: Perioperative application of 120mg ambroxol in patients with lung cancer undergoing single-port endoscopic lobectomy and lymphadenectomy can accelerate the recovery of patients, protect their lung function, inhibit inflammation, and improve their immune function and clinical symptoms. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
